- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07645066
Posterosuperior Bundle Pacing for Prevention of Atrial Fibrillation in Patients With Sinus Node Dysfunction (PSB-AF)
A Prospective, Multicenter, Randomized Controlled Trial Evaluating the Effect of Posterosuperior Bundle Pacing on Atrial Fibrillation Prevention in Patients With Sinus Node Dysfunction
This study aims to evaluate whether posterosuperior bundle (PSB) pacing reduces the incidence of atrial fibrillation (AF) in patients with sinus node dysfunction (SND) undergoing pacemaker implantation. Approximately 300 patients will be enrolled and randomized to receive atrial pacing at either the PSB region or the right atrial appendage (RAA). The primary endpoint is the occurrence of AF episodes lasting ≥6 minutes, as detected by device or surface electrocardiogram. Patients will be followed for up to 24 months.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Sinus node dysfunction (SND) is a common indication for permanent pacemaker implantation. Conventional right atrial appendage (RAA) pacing may result in delayed or dyssynchronous atrial activation, potentially increasing the risk of atrial arrhythmias. Posterosuperior bundle (PSB) pacing is a novel physiological atrial pacing approach. This study is a prospective, multicenter, open-label, randomized controlled trial. A total of approximately 300 eligible SND patients indicated for pacemaker implantation will be enrolled and randomly assigned (1:1) to PSB pacing or RAA pacing. Ventricular pacing will be performed using left bundle branch area pacing in both groups. Following implantation, the pacemaker will be programmed in DDD mode with a lower rate of 70 beats/min during daytime and 60 beats/min during nighttime. Rate-responsive pacing will be enabled by default when available; ATP will be disabled by default. Participants will be followed at 3, 6, 12, and 24 months after implantation. The primary endpoint is the occurrence of AF episodes lasting ≥6 minutes. Secondary endpoints include atrial high-rate episodes, AF burden, pacing parameters, ECG and echocardiographic indices, laboratory findings, and mortality outcomes. Safety endpoints include procedural complications and device-related adverse events.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Zhaohui Qiu
- Telefonnummer: +862152039999
- E-mail: qzh3503@shtrhospital.com
Studiesteder
-
-
Anhui
-
Anqing, Anhui, Kina
- Ikke rekrutterer endnu
- China Medical University affiliated AnQing Municipal Hospital
-
Kontakt:
- Liangchuan Chen
- Telefonnummer: +86 13956556381
- E-mail: aqslyy@163.com
-
Tongling, Anhui, Kina
- Ikke rekrutterer endnu
- Tongling People's Hospital
-
Kontakt:
- Ying Zhang
- Telefonnummer: +86 18005669636
- E-mail: tlph@mail.wh.ah.cn
-
-
Guizhou
-
Zunyi, Guizhou, Kina
- Ikke rekrutterer endnu
- Affiliated Hospital of Zunyi Medical College
-
Kontakt:
- Xianping Long
- Telefonnummer: +86 13885294999
- E-mail: longxianping1201@163.com
-
-
Hubei
-
Wuhan, Hubei, Kina
- Ikke rekrutterer endnu
- Wuhan Asia General Hospital
-
Kontakt:
- Hongwei Han
- Telefonnummer: +86 15327298622
- E-mail: wuhanagh@163.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200336
- Rekruttering
- Tong Ren Hospital, Shanghai Jiaotong University School of Medicine
-
Kontakt:
- Zhaohui Qiu
- Telefonnummer: +862152039999
- E-mail: qzh3503@shtrhospital.com
-
Shanghai, Shanghai Municipality, Kina
- Ikke rekrutterer endnu
- Fudan University affiliated Huadong Hospital
-
Kontakt:
- Zhengqi Kong
- Telefonnummer: +86 13816620347
- E-mail: huadongtexu@163.com
-
Shanghai, Shanghai Municipality, Kina
- Ikke rekrutterer endnu
- Shanghai Jiaotong University affiliated Shanghai Ninth People's Hospital
-
Kontakt:
- Zongqi Zhang
- Telefonnummer: +86 18049827281
- E-mail: zqzhang_scdc@126.com
-
Shanghai, Shanghai Municipality, Kina
- Ikke rekrutterer endnu
- Shanghai Jiaotong University affiliated Shanghai Sixth People's Hospital
-
Kontakt:
- Yisheng Pan
- Telefonnummer: +86 13817273883
- E-mail: shlygjyl@163.com
-
Shanghai, Shanghai Municipality, Kina
- Ikke rekrutterer endnu
- Shanghai University of Traditional Chinese Medicine affiliated Putuo Hospital
-
Kontakt:
- Zongjun Liu
- Telefonnummer: +86 19821577439
- E-mail: lzj72@126.com
-
Shanghai, Shanghai Municipality, Kina
- Ikke rekrutterer endnu
- Tongji University School of Medicine affiliated Tongji University
-
Kontakt:
- Bing Sun
- Telefonnummer: +86 13918324334
- E-mail: woowoocncn@163.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age ≥18 years
- Indication for permanent pacemaker implantation, including:
- Sinus node dysfunction, defined as at least one of the following:
- Symptomatic sinus bradycardia
- Tachy-brady syndrome
- Chronotropic incompetence
- Sinus pause / arrest
- Atrioventricular block (if present); if ventricular pacing is required, left bundle branch area pacing is planned
- Expected survival >1 year
- Panned implantation of a device capable of detecting atrial high-rate episodes
- Willing and able to provide informed consent
Exclusion Criteria:
- Persistent atrial fibrillation (AF) (>7 days), long-standing persistent AF, permanent AF, or prior atrioventricular node ablation
- Prior cardiac implantable electronic device (CIED) requiring replacement, upgrade, or revision
- Indication for cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT-D)
- Prior cardiac surgery, severe hepatic or renal dysfunction, or other life-threatening systemic diseases
- Acute myocardial infarction within 3 months before enrollment
- Persistent left superior vena cava or dextrocardia
- Pregnant or breastfeeding women, or women of childbearing potential not using effective contraception
- Participation in another clinical trial that may interfere
- Any condition that, in the opinion of the investigator, makes participation unsuitable
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: PSB pacing
Patients were randomly assigned to receive posterosuperior bundle pacing for atrial pacing during regular pacemaker implantation procedures. |
Atrial pacing lead implanted at the posterosuperior bundle region. Left bundle branch area pacing will be applied if ventricular pacing is necessary. |
|
Aktiv komparator: RAA pacing
Patients were randomly assigned to receive right atrial appendage pacing for atrial pacing during regular pacemaker implantation procedures. |
Atrial pacing lead implanted at the right atrial appendage. Left bundle branch area pacing will be applied if ventricular pacing is necessary. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of atrial fibrillation
Tidsramme: From implantation to regular follow-ups up to 24 months
|
Incidence of atrial fibrillation ≥ 6 minutes during follow-ups |
From implantation to regular follow-ups up to 24 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Atrial high-rate episodes
Tidsramme: From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
AF burden
Tidsramme: From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
eGFR
Tidsramme: At baseline, before discharge, and 6 - month follow-up
|
At baseline, before discharge, and 6 - month follow-up
|
|
|
All-cause mortality
Tidsramme: From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Cardiovascular death
Tidsramme: From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Intrinsic P-wave duration
Tidsramme: At baseline and regular follow-ups up to 24 months, when intrinsic atrial rhythm is assessable
|
Measured from the onset of the P wave to the end |
At baseline and regular follow-ups up to 24 months, when intrinsic atrial rhythm is assessable
|
|
Paced P-wave duration
Tidsramme: From implantation to regular follow-ups up to 24 months
|
Measured from the pacing stimulus to P wave end duration |
From implantation to regular follow-ups up to 24 months
|
|
Left ventricular ejection fraction (LVEF)
Tidsramme: At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
Left atrial diameter (LAD)
Tidsramme: At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
Right atrial diameter (RAD)
Tidsramme: At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
Left ventricular end-systolic diameter (LVESD)
Tidsramme: At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
Left ventricular end-diastolic diameter (LVEDD)
Tidsramme: At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
E/e'
Tidsramme: At baseline, 6-, 12- , 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12- , 24-month follow-ups
|
|
Mitral regurgitation severity
Tidsramme: At baseline, 6-, 12- , 24-month follow ups
|
Standard transthoracic echocardiographic measurement using standard semi-quantitative grading (none/trace, mild, moderate, or severe) |
At baseline, 6-, 12- , 24-month follow ups
|
|
Tricuspid regurgitation severity
Tidsramme: At baseline, 6-, 12-, 24- month follow-ups
|
Standard transthoracic echocardiographic measurement using standard semi-quantitative grading (none/trace, mild, moderate, or severe) |
At baseline, 6-, 12-, 24- month follow-ups
|
|
NT-pro BNP
Tidsramme: At baseline, before discharge, and 6-month follow-up
|
Standard transthoracic echocardiographic parameter |
At baseline, before discharge, and 6-month follow-up
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Atrial pacing capture threshold
Tidsramme: From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Atrial sensing amplitude
Tidsramme: From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Atrial pacing output
Tidsramme: From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Procedural complications
Tidsramme: Perioperative
|
Safety Outcome |
Perioperative
|
|
Postoperative adverse events
Tidsramme: From implantation to regular follow-ups up to 24 months
|
Safety Outcome, including lead-related complications, thromboembolic events, etc. |
From implantation to regular follow-ups up to 24 months
|
|
Paced P-wave morphology
Tidsramme: From implantation to regular follow-ups up to 24 months
|
positive, negative, notched, and biphasic |
From implantation to regular follow-ups up to 24 months
|
|
Intrinsic P-wave morphology
Tidsramme: At baseline, implant, and regular follow-ups up to 24 months when intrinsic atrial rhythm is assessable
|
positive, negative, notched, and biphasic |
At baseline, implant, and regular follow-ups up to 24 months when intrinsic atrial rhythm is assessable
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
- PSB-AF
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .